Alan Kennedy

9PUBLICATIONS
50CO-AUTHORS
Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cellular immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 29, 2026
Immune dysregulation from a novel CTLA-4 haploinsufficiency variant.

Nina N Brodsky, Alan Kennedy, Daniel Glaser

|Jul 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.

Brianna M Lax, Joseph R Palmeri, Emi A Lutz

|Feb 02, 2023
The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.

Alan Kennedy, Maximillian A Robinson, Claudia Hinze

|Oct 26, 2022
Therapeutic gene editing of T cells to correct CTLA-4 insufficiency.

Thomas Andrew Fox, Benjamin Christopher Houghton, Lina Petersone

|Aug 23, 2022
Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation.

Alan Kennedy, Erin Waters, Behzad Rowshanravan

|May 07, 2021
Regulation of CTLA-4 recycling by LRBA and Rab11.

Daniel Janman, Claudia Hinze, Alan Kennedy

Pageof 2

Frequent Collaborators

8 joint publications

David Michael Sansom

4 joint publications

Claudia Hinze

3 joint publications

Neil Halliday

3 joint publications

Emma Catherine Morris